GlassScriptPhysician profile
Bing Shue
NPI 1508120106
$48,962.25
in general payments reported to CMS, 2019-2025
26 companies · $13K in 2025
The $13K reported for 2025 was more than what 92% of Vascular Surgery providers received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $888 · 2020: $513 · 2021: $383 · 2022: $3,011 · 2023: $15K · 2024: $17K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $42K · Food and Beverage: $2,566 · Travel and Lodging: $16.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $41,583.34 |
| Food and Beverage | $2,565.89 |
| Travel and Lodging | $16.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $44,261.97 | 2022-2025 | Auryon Laser System 100-120 Vac, Auryon Laser System 100-120 Vac |
| Medtronic, INC. | $866.99 | 2022-2023 | Endurant Iis, Venaseal |
| Janssen Pharmaceuticals, INC | $806.48 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $681.36 | 2019-2024 | Varithena Administration Pack |
| Smith+Nephew, INC. | $642.22 | 2019-2025 | Grafix Pl, Stravix, Renasys Touch |
| Endologix LLC | $278.01 | 2023-2025 | Alto Abdominal Stent Graft System |
| Philips North America LLC | $228.34 | 2019-2024 | (5573) Duo Hybrid |
| Tactile Systems Technology INC | $151.44 | 2019-2024 | Entre Plus, Flexitouch Plus |
| E.R. Squibb & Sons, L.L.C. | $148.00 | 2019-2025 | Eliquis |
| Inari Medical, INC. | $141.84 | 2022-2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Medtronic Vascular, INC. | $140.22 | 2019-2020 | |
| Pfizer INC. | $131.29 | 2019-2023 | |
| Lemaitre Vascular, INC. | $82.50 | 2019-2024 | Artegraft Vascular Graft |
| Abbott Laboratories | $62.19 | 2022-2023 | Jeti Peripheral Catheter |
| Cardiovascular Systems INC. | $51.94 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kci USA, INC. | $48.64 | 2021-2023 | Activ.A.C. |
| Paratek Pharmaceuticals, INC. | $35.21 | 2022-2023 | Nuzyra |
| Koya Medical, INC. | $31.17 | 2025 | Koya Medical, Dayspring |
| Solventum Corporation | $29.92 | 2025 | Activ.A.C. |
| Biocompatibles, INC. | $24.27 | 2019 | |
| Asahi Intecc USA, INC. | $22.08 | 2024 | Peripheral Vascular |
| Kerecis Limited | $21.30 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Cordis US Corp. | $21.01 | 2024 | Radial 360 |
| Urgo Medical North America, LLC | $20.18 | 2024 | Urgoclean Ag |
| Janssen Scientific Affairs, LLC | $17.94 | 2022 | |
| Reprise Biomedical, INC. | $15.74 | 2023 | Miro3d Fibers, Miroflex, Miro3d |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bing Shue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.